Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 215825, held by Xiromed. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 215825 (Ephedrine Sulfate), held by Xiromed, was first approved by FDA on Apr 21, 2022, with 0 approved supplements and 0 published complete response letters.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters